Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KISS1R | Q969F8 | 7/20 | 0.59 |
| ▸ | IL23R | Q5VWK5 | 6/20 | 0.57 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.56 |
| ▸ | NPBWR1 | P48145 | 2/20 | 0.55 |
| ▸ | CCKBR | P32239 | 2/20 | 0.55 |
| ▸ | CCKAR | P32238 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30028948 | 0.98 | KISS1R (0.57) | KISS1RIL23ROPRD1OPRM1NPBWR1 | |
| SCHEMBL29476584 | 0.93 | KISS1R (0.60) | KISS1RIL23ROPRD1OPRM1NPBWR1 | |
| SCHEMBL30264831 | 0.93 | KISS1R (0.59) | KISS1RIL23ROPRD1OPRM1NPBWR1 | |
| SCHEMBL29511018 | 0.93 | KISS1R (0.58) | KISS1RIL23ROPRD1OPRM1 | |
| SCHEMBL29511037 | 0.93 | KISS1R (0.58) | KISS1RIL23ROPRD1OPRM1 | |
| SCHEMBL31256969 | 0.92 | KISS1R (0.63) | KISS1ROPRD1OPRM1NPBWR1CCKBR | |
| SCHEMBL31206256 | 0.90 | KISS1R (0.55) | KISS1RIL23ROPRD1OPRM1 | |
| SCHEMBL29476439 | 0.89 | KISS1R (0.55) | KISS1RIL23ROPRD1OPRM1NPBWR1 | |
| SCHEMBL29476441 | 0.89 | KISS1R (0.55) | KISS1RIL23ROPRD1OPRM1NPBWR1 | |
| SCHEMBL30264981 | 0.89 | ACE (0.53) | KISS1RIL23RNPBWR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220339239-A1 | USE OF MELANOCORTINS TO TREAT INSULIN SENSITIVITY | IPSEN PHARMA SAS (FR) | 2022-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220339239-A1 | USE OF MELANOCORTINS TO TREAT INSULIN SENSITIVITY | MC4R, MC1R, MC3R | KISS1R 155/4885IL23R 301/4885OPRD1 359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.